NewAmsterdam Pharma Co N.V (NAMS) Research & Development: 2022-2025
Historic Research & Development for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $31.0 million.
- NewAmsterdam Pharma Co N.V's Research & Development fell 13.25% to $31.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.1 million, marking a year-over-year decrease of 12.46%. This contributed to the annual value of $151.4 million for FY2024, which is 5.03% down from last year.
- NewAmsterdam Pharma Co N.V's Research & Development amounted to $31.0 million in Q3 2025, which was up 12.56% from $27.5 million recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma Co N.V's Research & Development ranged from a high of $44.8 million in Q1 2025 and a low of -$31.2 billion during Q4 2022.
- Over the past 3 years, NewAmsterdam Pharma Co N.V's median Research & Development value was $38.4 million (recorded in 2024), while the average stood at $37.6 million.
- As far as peak fluctuations go, NewAmsterdam Pharma Co N.V's Research & Development soared by 100.13% in 2023, and later fell by 28.30% in 2025.
- Quarterly analysis of 4 years shows NewAmsterdam Pharma Co N.V's Research & Development stood at -$31.2 billion in 2022, then skyrocketed by 100.13% to $41.3 million in 2023, then fell by 15.49% to $34.9 million in 2024, then dropped by 13.25% to $31.0 million in 2025.
- Its Research & Development stands at $31.0 million for Q3 2025, versus $27.5 million for Q2 2025 and $44.8 million for Q1 2025.